Affordable Access

Treatment of E2E2 homozygous familial dysbetalipoproteinemic subjects with gemfibrozil does not enhance the binding of their d < 1.019 lipoprotein fraction to the low-density lipoprotein receptor.

Authors
  • Mulder, M
  • Smelt, A H
  • Zhao, S P
  • Frants, R R
  • Havekes, L M
Type
Published Article
Journal
Metabolism
Publisher
Elsevier
Publication Date
Mar 01, 1993
Volume
42
Issue
3
Pages
327–333
Identifiers
PMID: 8487651
Source
Medline
License
Unknown

Abstract

Six E2E2 homozygous familial dysbetalipoproteinemic (FD) patients were treated with gemfibrozil (2 x 600 mg/d) for a period of 4 weeks. For all subjects, normalization of serum cholesterol concentrations with treatment did not result in a significant change in the cholesterol/triglyceride ratio of the d < 1.019 lipoprotein fraction. In addition, the binding efficiency of this lipoprotein fraction to the low-density lipoprotein (LDL) receptor on HepG2 cells did not change consistently with treatment. We conclude that normalization of serum cholesterol concentrations in FD patients by treatment with gemfibrozil is the result of an effect of gemfibrozil on the synthesis of d < 1.019 lipoproteins rather than an effect on the receptor-mediated clearance of these particles.

Report this publication

Statistics

Seen <100 times